Published in J Cataract Refract Surg on March 01, 1990
Mitomycin against posterior capsular opacification: an experimental study in rabbits. Br J Ophthalmol (1996) 0.89
F-heparin modified intraocular lenses in Rhesus monkeys. Int J Ophthalmol (2010) 0.79
Exposure to organic solvents. A cross-sectional epidemiologic investigation on occupationally exposed care and industrial spray painters with special reference to the nervous system. Scand J Work Environ Health (1980) 2.67
Genetic typing of classical swine fever virus. Vet Microbiol (2000) 2.31
Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation (2000) 1.83
Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci (2000) 1.74
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes (1999) 1.65
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs (2001) 1.33
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant (1997) 1.33
Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol (1998) 1.30
A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs (1983) 1.25
ATP is required for in vitro assembly of MHC class I antigens but not for transfer of peptides across the ER membrane. Cell (1991) 1.23
Spontaneous systemic lupus erythematosus and acelylator phenotype. Acta Med Scand (1977) 1.19
Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant (1994) 1.17
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer (2003) 1.16
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 1.11
Active oxygen induced DNA strand breakage and poly ADP-ribosylation in promotable and non-promotable JB6 mouse epidermal cells. Carcinogenesis (1988) 1.07
Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int (1998) 1.07
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol (1982) 1.04
Reciprocal inhibition during the tonic stretch reflex in the decerebrate cat. J Physiol (1978) 1.04
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 1.02
The effects of cimetidine (Tagamet) on renal function in patients with renal failure. Acta Med Scand (1980) 1.01
Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand (1977) 1.01
The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. Acta Med Scand (1979) 1.01
Coexistence of neuronal messengers--an overview. Prog Brain Res (1986) 0.99
Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf (1996) 0.99
A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials (1999) 0.99
Short- and long-term treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine. Scand J Gastroenterol Suppl (1979) 0.98
Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol (2000) 0.98
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res (1999) 0.97
Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. Cell Tissue Res (1986) 0.96
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med (2002) 0.95
End-stage chronic renal failure due to total uterine prolapse. Acta Obstet Gynecol Scand (1982) 0.95
Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther (1981) 0.94
Contact between a polymer and whole blood: sequence of events leading to thrombin generation. J Lab Clin Med (2001) 0.94
Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol (1996) 0.94
The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy (2007) 0.94
Sensory reinnervation and sensibility after superficial skin wounds in human patients. Neurosci Lett (1987) 0.93
Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull (1986) 0.93
Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med (2003) 0.93
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther (1998) 0.93
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
Laminin immunohistochemistry: a simple method to visualize and quantitate vascular structures in the mammalian brain. J Neurosci Methods (1986) 0.93
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs (1992) 0.93
Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol (1998) 0.92
Immunohistochemical demonstration of glial fibrillary acidic protein in normal rat Müller glia and retinal astrocytes. Neurosci Lett (1985) 0.92
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol (1995) 0.92
Intestinal microsporidiosis in a HIV-seronegative patient. Scand J Infect Dis (1998) 0.91
N-myc and c-src genes are differentially regulated in PCC7 embryonal carcinoma cells undergoing neuronal differentiation. J Cell Physiol (1986) 0.91
Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol (1985) 0.91
Differential morphological changes in sympathetic nerve fibers elicited by lead, cadmium, and mercury. Environ Res (1981) 0.91
Neurofilament and glial fibrillary acid protein-related immunoreactivity in rodent enteric nervous system. Neuroscience (1984) 0.90
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol (1994) 0.90
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer (1996) 0.89
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer (1999) 0.89
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol (1998) 0.89
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer (1994) 0.89
Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials (2001) 0.89
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem Pharmacol (2001) 0.89
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer (1991) 0.89
1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int (1988) 0.88
Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis. Thromb Haemost (1999) 0.88
Disordered catecholamine release in pigs susceptible to malignant hyperthermia. Pharmacol Toxicol (1988) 0.88
Astrocytes in smears of CNS tissues as visualized by GFA and vimentin immunofluorescence. Med Biol (1984) 0.87
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs (1994) 0.87
Oxidants stress induces the proto-oncogenes, C-fos and C-myc in mouse epidermal cells. Bull Cancer (1990) 0.87
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol (1996) 0.87
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer (1991) 0.86
Description and analysis of two internet-based databases of insect pathogens: EDWIP and VIDIL. J Invertebr Pathol (2003) 0.86
Image analysis of GFA-positive astrocytes from adolescence to senescence. Exp Brain Res (1985) 0.86
Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes. Brain Res (1986) 0.86
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J Pharmacol Exp Ther (2001) 0.86
Distribution of neurofilament-immunoreactive nerve fibers in human skin. Histochemistry (1984) 0.86
Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. Eur J Clin Pharmacol (1982) 0.85
Characterization and mechanism of formation of reactive products formed during peroxidase-catalyzed oxidation of p-phenetidine. Trapping of reactive species by reduced glutathione and butylated hydroxyanisole. Mol Pharmacol (1985) 0.85
Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells. Cell Mol Life Sci (2003) 0.85
Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: implication for parathyroid autotransplantation. World J Surg (1988) 0.85
Pathophysiological mechanisms of active oxygen. Mutat Res (1989) 0.85
Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration. Biosci Rep (1990) 0.85
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer (1997) 0.85
Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia (1992) 0.85
DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res (2002) 0.85
Inhibition of thrombin on surfaces coated with immobilized heparin and heparin-like polysaccharides: a crucial non-thrombogenic principle. Thromb Res (1981) 0.85
Calcium-activated calcium permeability in parathyroid cells. FEBS Lett (1986) 0.84
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1997) 0.84
Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol (2005) 0.84
Appearance of the noradrenergic markers tyrosine hydroxylase and neuropeptide Y in cholinergic nerves of the iris following sympathectomy. J Neurosci (1985) 0.84
Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol (1979) 0.84
Genetic diversity of equine arteritis virus. J Gen Virol (1999) 0.84
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB. Biochem Pharmacol (2000) 0.84
Absorption, distribution and excretion of the anthelmintic praziquantel (Droncit) in rainbow trout (Salmo gairdneri R.). Parasitol Res (1987) 0.84
Some toxic effects of lead, other metals and antibacterial agents on the nervous system--animal experiment models. Acta Neurol Scand Suppl (1984) 0.83
Kinetic evidence for cytoplasmic calcium as an inhibitory messenger in parathyroid hormone release. Biochim Biophys Acta (1988) 0.83
Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol (1996) 0.83
Infrared radiation and cataract. Acta Ophthalmol Suppl (1984) 0.83
Characterization of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance. Biomaterials (2003) 0.83
Calcium-agonistic action of Mn2+ in the parathyroid cell. Mol Cell Endocrinol (1988) 0.83
Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine. Biochem Pharmacol (2000) 0.83
[Effect and concentration in plasma of metoprolol after administration in the morning and in the evening in essential hypertension]. Lakartidningen (1978) 0.83
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer (2000) 0.83